Synergistic Mechanism of Interferon alpha-1b, Interleukin-2 and Thalidomide for Immune Regulation in Patients with Acute Myeloid Leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 26-31, 2021.
Article
in Zh
| WPRIM
| ID: wpr-880026
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To explore the synergistic immunomodulatory mechanism of interferon alpha-1b, interleukin-2 and thalidomide (ITI) regimen on patients with acute myeloid leukemia (AML).@*METHODS@#Sixty eight untreated de novo or relapsed or refractory or maintenance therapy patients with AML admitted in the Affiliated Cancer Hospital of Zhengzhou University and the other 11 medical units from March 2016 to May 2019 were treated with ITI regimen. Peripheral blood specimen per patient was collected into EDTA-K3 anticoagulation vacuum tube before the administration of ITI and 3 months after the treatment; peripheral blood lymphocyte subsets and perforin and Granzyme B expression were analyzed by using flow cytometry; the levels of VEGF, IFN-γ, TNF-α and IL-6 in the plasma were detected by using a cytometric bead array. Thirty-five healthy subjects from the hospital physical examination centre were selected as normal controls.@*RESULTS@#The ratio of CD4@*CONCLUSION@#The ITI regimen can raise the ratio of CD4
Full text:
1
Database:
WPRIM
Main subject:
Thalidomide
/
Leukemia, Myeloid, Acute
/
Interleukin-2
/
Interferon-alpha
/
CD8-Positive T-Lymphocytes
/
Perforin
Limits:
Humans
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2021
Document type:
Article